2-(2,3-Dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 97%, 1g

N-(3-Fluorophenyl)piperidin-4-amine hydrochloride, 95.0%, 10g

N'-(4-Fluoro-benzyl)-N,N-dimethyl-ethane-1,2-diamine, 250mg

METHYL-[3-METHYL-5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDIN-2-YL]-AMINE, 95%, 500mg

5-Amino-2-chloroisonicotinic acid, 95.0%, 5g

methyl 3-(1H-1,2,3,4-tetrazol-5-yl)benzoate, 95%, 100mg

3,5-Bis(ethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-4-carboxylic Acid>95.0%(HPLC)(T)1g

2-Methyl-1,2,3,4-tetrahydroquinolin-8-ol hydrochloride, 98%, 5g

3-Oxo-indan-5-carbonitrile, 95.0%, 25g

2-(2,4-Difluorophenyl)benzaldehyde, 98+%, 500mg

N-methyltetrahydro-2H-thiopyran-4-amine, 95.0%, 10g

HPLC column NUCLEODUR® 100-3 C8 ec, 150 mm, 4.6 mm, 1 Piece(s)

1-(3-Fluoropyridin-2-yl)ethan-1-ol, 95+%, 250mg